Equities researchers at JPMorgan Chase & Co. initiated coverage on shares of Electra Therapeutics (NASDAQ:ETRA – Get Free Report) in a report released on Thursday, Briefing.com reports. The firm set an “overweight” rating and a $36.00 price target on the stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 297.79% from the company’s current price.
ETRA has been the subject of several other research reports. Cantor Fitzgerald began coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They issued an “overweight” rating for the company. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. Evercore assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set an “outperform” rating and a $36.00 target price for the company. TD Cowen began coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating for the company. Finally, Jefferies Financial Group began coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating and a $32.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $34.67.
View Our Latest Stock Analysis on ETRA
Electra Therapeutics Stock Up 2.7%
Shares of NASDAQ ETRA opened at $9.05 on Thursday. Electra Therapeutics has a 1 year low of $8.50 and a 1 year high of $15.50.
Insider Buying and Selling at Electra Therapeutics
In other Electra Therapeutics news, Director Carl Gordon bought 1,333,333 shares of Electra Therapeutics stock in a transaction dated Monday, September 21st. The stock was bought at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the acquisition, the director directly owned 5,126,891 shares of the company’s stock, valued at approximately $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc purchased 1,333,333 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the transaction, the director directly owned 5,126,891 shares of the company’s stock, valued at $76,903,365. This trade represents a 35.15% increase in their position. The disclosure for this purchase is available in the SEC filing.
Electra Therapeutics Company Profile
Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.
Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.
Read More
- Five stocks we like better than Electra Therapeutics
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
